(UPDATED Oct. 4, 2013 with comment from 340B hospitals.) October 2, 2013—Pharmaceutical Research and Manufacturers of America (PhRMA) filed suit in federal district court on Sept. 27 to stop the Department of Health and Human Services (HHS) and the Health Resources and Services Administration (HRSA) from implementing HRSA’s regulation setting conditions under which critical access hospitals, sole community hospitals, rural referral centers, and free-standing cancer hospitals may purchase orphan drugs through the 340B drug discount program.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)